Predictive modelling of level IIb lymph node metastasis in oral squamous cell carcinoma

Hyunwoo Yang1,3, Nak-Hoon Son2,3, Sung Hwa Lee1, Dongwook Kim1, Hyung Jun Kim1, In-ho Cha1 & Woong Nam1*

The aim of the present study was to examine the conditions, characteristics, and risk factors of level IIb lymph node metastases in oral squamous cell carcinoma and to formulate surgical criteria for level IIb lymph node dissection. We analyzed clinical and pathological records for 541 oral squamous carcinoma patients in relation to level IIb metastasis. Univariate and multivariate analyses were performed to detect risk factors for level IIb lymph node metastasis; a predictive model was built based on multivariate analysis and tested in a validation group. Univariate and multivariate analyses using the training group indicated that level IIa metastasis and Lymphovascular permeation (LVP) were two independent risk factors for level IIb lymph node metastasis. This model was built and tested in a validation group, the area under the curve being 0.697 (P < .001). The model’s sensitivity was 66.7% and specificity was 77.4%. Nomogram incorporating validated variables was developed for level IIb metastasis prediction. Expected survival probabilities were analysed to specify significance of model’s variable on patients’ overall survival and recurrence. Level IIb dissection should be performed in patients with level IIa metastasis and LVP. However, thorough consideration of the oncologic safety of omitting level IIb dissection is compulsory.

Oral cancer is a global problem, with over 350,000 new patients each year and more than 170,000 deaths1. Paradoxically, a majority of cases are detected at an advanced stage, slightly more than half of patients surviving 5 years despite a well-defined tumor progression model and relatively amenable examination2. Cervical lymph node metastases in oral squamous cell carcinoma (OSCC), which account for more than 90% of oral malignancies, are common. The presence of lymph node metastasis is one of the most adverse prognostic factors in OSCC3. It has been reported clinically evident in approximately 40% of patients, with occult disease rates ranging from 15 to 34%4. Consequently, OSCC is often treated with simultaneous neck dissection for either therapeutic, diagnostic, or prophylactic purposes. After Virchow first formulated the definition and emphasized the metastatic trend of malignant lesions in 1885 through "Cellular pathology", neck dissection as currently conceived emerged6,7. Later, radical neck dissection was introduced, becoming the standard in managing oral cancer metastatic lymph node8. However, recognizing that morbidity was clearly associated with the increasing extent of neck dissections, surgeons consistently sought to decrease the extent to achieve a balance between oncologic safety and acceptable morbidity9. Due to their invasive nature, radical neck dissections are now performed only for patients with large metastatic nodes with extranodal extension into the non-lymphatic structures10. In line with such atmosphere, modified radical neck dissection (MRND) or functional neck dissection (FND), which preserves major anatomical structures while dissecting lymphatic group was introduced and performed11. There is also an overall consensus for performing selective neck dissections (SND) rather than modified radical neck dissections (MRND) for patients with clinical node-negative necks12. In spite of such gradual establishment of protocol for treating neck in OSCC patients, there is an ongoing debate concerning dissection of level IIb in both node-negative and positive patients, primarily due to the low incidence of metastasis in this region and possible injury to the spinal accessory nerve (SAN)9. Previous studies have argued for and against dissecting level IIb based on descriptive results regarding the level IIb lymph node metastasis rate13,14. However, to our knowledge, no predictive model has been generated to assist decision on extending dissection of level IIb compartment based on a OSCC patient cohort. In this study, we conducted a multi-spectral analysis of the frequency and pattern of
level IIb lymph node metastases, detected risk factors, and built a predictive model based on these risk factors with a large OSCC patient cohort.

**Results**

**Clinicopathologic characteristics.** Of the 359 patients whose records were suitable for analysis, 139 were in early stages (I-II) and 220 patients in developed stages (III-IV) according to the American Joint Committee on Cancer (AJCC) 8th edition Cancer Staging Manual. Among them, 12 patients had level IIb metastasis with three isolated metastases. Table 1 presents the clinical characteristics of the dataset.

All 359 OSCC patients who underwent neck dissection were split randomly into two mutually exclusive groups: a training group of 224 patients to detect risk factors for level IIb lymph node metastasis and build a predictive model and a validation group of 135 patients to verify the model. There were no statistically significant differences in variables between the two sets (Table 2).

**Risk factors for level IIb lymph node metastasis by univariate and multivariate analyses.** To investigate risk factors for level IIb lymph node metastasis, 20 categorical and numerical variables were included (Table 3) in a univariate analysis of the training group (n = 224). The following factors were associated with level IIb lymph node metastasis: LVP (OR = 10.24; p = 0.014), level IIA metastasis (OR = 9.80; p = 0.004), level III metastasis (OR = 11.77; p = 0.003), level IV metastasis (OR = 17.92, p = 0.026), and level V metastasis (OR = 17.92, p = 0.026).

Statistically significant variables from the univariate analysis were included in the multivariate analysis. As shown in Table 4, predictors of level IIb lymph node metastasis included LVP with an OR (95% confidence interval [CI]) of 7.59 (1.01, 68.29) and level IIA metastasis with an OR (95% CI) of 14.25 (1.91, 128.42).

**Predictive model and nomogram for level IIb lymph node metastasis.** Based on multivariate analysis, we built a model to predict level IIb lymph node metastasis. The equation was as follows: logit[P]= -4.708+2.026×LVP+2.656×Level IIa metastasis. Receiver operating curve for the validation group is depicted in Fig. 1. The area under the curve (AUC) was 0.697, and the P value was less than 0.001. Cut-off value of this model was determined by the Youden index (maximum potential effectiveness of a biomarker). Based on the cutoff value, the sensitivity was 66.7% and specificity 74.4%, with a model accuracy of 74.1%. To promote clinical applicability and increase user-friendliness, estimation nomogram for level IIb metastasis was developed utilizing variables(LVP, level IIa) obtained from Cox proportional hazard model (Fig. 2). Each variable in the model corresponds to a score, the sum of each score becomes a total score. The total scores ranges from 0 to 180, with corresponding metastasis risk of 0.05 to 0.45. The higher the score, the higher risk of level IIb metastasis.

**Survival analysis of OSCC patients according to follow up time.** Extending the justification for LVP and level IIA, expected survival probabilities were analysed in the context of recurrence and overall death. Based on cox proportional hazard regression, hazard ratios of LVP and Level IIa were combined into following four cases: LVP positive/Level IIA negative, LVP negative/Level IIA negative, LVP negative/Level IIA positive, and LVP positive/Level IIA positive(Fig. 3). Survival plots revealed Level IIA metastasis had relatively stronger impact on recurrence and overall survival.

**Discussion**

Many previous studies have made it clear that the pattern of cervical nodal spread in OSCC patients follows a somewhat predictable pathway. Subsequently, extent of neck dissection, which primarily depends on the pattern and tumor subsite, has gradually become circumscribed to cervical levels I, II and III even in node-positive cases. Cervical level II, however, remains one of the most prevalent regions of OSCC metastasis, requiring meticulous dissection. Level IIb, referred to as “submuscular recess,” however, remains an area of controversy. The SAN itself serves as an anatomical border splitting level II into sublevels IIa and IIb. To adequately remove this level being only 0.3% metastases. We found similar results in the present study, with an overall incidence of 3.3% at level IIb. Despite such results and the risk of shoulder morbidity, studies have failed to clear the air concerning this issue, primarily due to lack of definitive evidence regarding oncological safety in avoiding submuscular recess dissection. In various other published studies, authors seem reluctant to reach a conclusion on the necessity of level IIb dissection, only noting that the issue merits further discussion. This uncertainty has led researchers to seek clinical criteria for level IIb dissection based on risk factors to level IIb metastasis.

To establish a customized neck dissection protocol, the present study developed a model using clinicopathological parameters to predict the nodal status of level IIb. Based on the model, level IIA metastasis and LVP were predictors of level IIb metastasis. A majority of studies concur that positive nodes at level IIA predict level IIb metastases. However, to the best of our knowledge, this is the first report of an independent association between LVP and level IIb metastasis in an OSCC patient cohort. Our predictive model indicates that the
### Table 1. Baseline characteristics. Data were reported as mean ± standard deviation (SD) or median [Q1–Q3] for continuous variables and n (%) for categorical variables. *According to AJCC 8th classification. pN pathologic N, cT clinical T, cN clinical N.

| Variable                          | N   | Total                          |
|-----------------------------------|-----|-------------------------------|
| **Sex**                           | 359 |                               |
| Male                              | 235 (65.5%) |
| Female                            | 124 (34.5%) |
| **Ages**                          | 359 | 59.3 ± 11.7                  |
| **TNM stage**                     | 359 |                               |
| Early (I–II)                      | 139 (38.7%) |
| Developed (III–IV)                | 220 (61.3%) |
| **pN**                            | 359 |                               |
| N0                                | 212 (59.1%) |
| N+                                | 147 (40.9%) |
| **cT**                            | 359 |                               |
| Early (T1–T2)                     | 52 (14.5%) |
| Developed (T3–T4)                 | 307 (85.5%) |
| **cN**                            | 359 |                               |
| N0                                | 207 (57.7%) |
| N+                                | 152 (42.3%) |
| **Site**                          | 359 |                               |
| Buccal cheek                      | 36 (10.0%) |
| Floor of mouth                    | 25 (7.0%) |
| Lip                               | 2 (0.6%)  |
| Mandible                          | 120 (33.4%) |
| Maxilla                           | 45 (12.5%) |
| Retromolar trigone                | 36 (10.0%) |
| Tongue                            | 95 (26.5%) |
| **Resection margins**             | 359 |                               |
| Free                              | 252 (70.2%) |
| Dysplasia                         | 25 (7.0%)  |
| Presence                          | 82 (22.8%)  |
| **Histologic grade**              | 343 |                               |
| Well differentiated               | 53 (15.5%)  |
| Moderately differentiated         | 233 (67.9%)  |
| Poorly differentiated             | 57 (16.6%)  |
| **Bone marrow invasion**          | 160 |                               |
| No                                | 22 (13.8%)  |
| Yes                               | 138 (86.2%)  |
| **Perineural invasion**           | 225 |                               |
| No                                | 187 (83.1%)  |
| Yes                               | 38 (16.9%)  |
| **Lymphovascular permeation**     | 223 |                               |
| No                                | 186 (83.4%)  |
| Yes                               | 37 (16.6%)  |
| **Depth of invasion**             | 77  | 8.0 [6.0–15.0]               |
| **Extra nodalextension**          | 141 |                               |
| Yes                               | 50 (35.5%)  |
| No                                | 91 (64.5%)  |
| **Neck levels of metastatic lymph node** |      |                               |
| Ia                                 | 11 (3.1%)  |
| Ib                                 | 63 (17.5%)  |
| IIa                                | 46 (12.8%)  |
| IIb                                | 12 (3.3%)  |
| III                                | 20 (5.6%)  |
| IV                                 | 6 (1.7%)  |
| V                                  | 4 (1.1%)  |
combined risk factors of level IIa metastasis and LVP significantly raise the level IIb metastasis rate. Our OSCC patient cohort comprises patients of all stages. Regarding unpredictable aspects of developed stage (III–IV) patients, our model exhibits comprehensive and decent performance, with an c-index (Harell’s) of 0.697 and model accuracy of 74.1%.

Table 2. Baseline characteristics, training and validation groups. Data were reported as mean ± standard deviation (SD) or median [Q1–Q3] for continuous variables and n (%) for categorical variables. P values were calculated by Student’s t-test or Mann–Whitney U test for continuous variables and chi-square test or Fisher’s exact test for categorical variables. pN pathologic N, cT clinical T, cN clinical N.

| Variable                        | Training (N = 224) | Validation (N = 135) | p value |
|---------------------------------|--------------------|----------------------|---------|
| Sex                             |                    |                      | 0.375   |
| Male                            | 151 (67.4%)        | 84 (62.2%)           |         |
| Female                          | 73 (32.6%)         | 51 (37.8%)           |         |
| Age                             | 59.0 ± 11.6        | 59.8 ± 12.0          | 0.531   |
| TNM stage                       |                    |                      | 0.863   |
| Early (T1–T2)                   | 88 (39.3%)         | 51 (37.8%)           |         |
| Developed (T3–T4)               | 136 (60.7%)        | 84 (62.2%)           |         |
| pN                              |                    |                      | 0.787   |
| N0                              | 134 (59.8%)        | 78 (57.8%)           |         |
| N+                              | 90 (40.2%)         | 57 (42.2%)           |         |
| cT                              |                    |                      | 0.222   |
| Early (T1–T2)                   | 28 (12.5%)         | 24 (17.8%)           |         |
| Developed (T3–T4)               | 196 (87.5%)        | 111 (82.2%)          |         |
| cN                              |                    |                      | 1.000   |
| N0                              | 129 (57.6%)        | 78 (57.8%)           |         |
| N+                              | 95 (42.4%)         | 57 (42.2%)           |         |
| Site                            |                    |                      | 0.889   |
| Buccal cheek                    | 24 (10.7%)         | 12 (8.9%)            |         |
| Floor of mouth                  | 14 (6.2%)          | 11 (8.1%)            |         |
| Lip                             | 2 (0.9%)           | 0 (0.0%)             |         |
| Mandible                        | 71 (31.7%)         | 49 (36.3%)           |         |
| Maxilla                         | 28 (12.5%)         | 17 (12.6%)           |         |
| Retromolar trigone              | 24 (10.7%)         | 12 (8.9%)            |         |
| Tongue                          | 61 (27.2%)         | 34 (25.2%)           |         |
| Resection margins               |                    |                      | 0.066   |
| Free                            | 152 (67.9%)        | 100 (74.1%)          |         |
| Dysplasia                       | 21 (9.4%)          | 4 (3.0%)             |         |
| Presence                        | 51 (22.8%)         | 31 (23.0%)           |         |
| Histologic grade                |                    |                      | 0.246   |
| Well                            | 32 (15.0%)         | 21 (16.2%)           |         |
| Moderate                        | 140 (65.7%)        | 93 (71.5%)           |         |
| Poor                            | 41 (19.2%)         | 16 (12.3%)           |         |
| Bone marrow invasion            |                    |                      | 0.352   |
| No                              | 11 (11.2%)         | 11 (17.7%)           |         |
| Yes                             | 87 (88.8%)         | 51 (82.3%)           |         |
| Perineural invasion             |                    |                      | 0.542   |
| No                              | 121 (84.6%)        | 66 (40.5%)           |         |
| Yes                             | 22 (15.4%)         | 16 (19.5%)           |         |
| Lymphovascular permeation       |                    |                      | 0.374   |
| No                              | 118 (85.5%)        | 68 (80.0%)           |         |
| Yes                             | 20 (14.5%)         | 17 (20.0%)           |         |
| Depth of invasion               | 8.0 [ 6.0—13.0]    | 8.0 [ 7.0—15.0]      | 0.715   |
| Extra-nodal extension           |                    |                      | 0.238   |
| No                              | 58 (69.0%)         | 33 (57.9%)           |         |
| Yes                             | 26 (31.0%)         | 24 (42.1%)           |         |
| Variable                  | Univariable | p value   |
|--------------------------|-------------|-----------|
|                          | OR (95% CI) |           |
| **Sex**                  |             |           |
| Male                     | 1           |           |
| Female                   | 0.82 (0.12, 3.92) | 0.818     |
| **Age**                  | 1.00 (0.94, 1.07) | 0.945     |
| **TNM stage**            |             |           |
| Early (I–II)             | 1           |           |
| Developed (III–IV)       | 1.64 (0.35, 11.64) | 0.559     |
| **pN**                   |             |           |
| N0                       | 1           |           |
| N +                      | 195,904,539 (0.00, Inf) | 0.994     |
| **cT**                   |             |           |
| Early (T1–T2)            | 1           |           |
| Developed (T3–T4)        | 0.85 (0.19, 16.43) | 0.885     |
| **cN**                   |             |           |
| N0                       | 1           |           |
| N +                      | 3.53 (0.74, 25.02) | 0.137     |
| **Site**                 |             |           |
| Buccal cheek             | 1           |           |
| Floor of mouth           | 1.00 (0.00, Inf) | 1.000     |
| Lip                      | 1.00 (0.00, Inf) | 1.000     |
| Mandible                 | 9,112,058 (0.00, Inf) | 0.994     |
| Maxilla                  | 11,643,185 (0.00, Inf) | 0.994     |
| Retromolar trigone       | 28,578,726 (0.00, Inf) | 0.994     |
| Tongue                   | 10,656,474 (0.00, Inf) | 0.994     |
| **Resection margins**    |             |           |
| Free                     | 1           |           |
| Dysplasia                | 0.00 (0.00, Inf) | 0.996     |
| Presence                 | 0.00 (0.00, Inf) | 0.994     |
| **Histologic grade**     |             |           |
| Well                     | 1           |           |
| Moderate                 | 0.68 (0.08, 13.97) | 0.741     |
| Poor                     | 2.45 (0.30, 50.82) | 0.448     |
| **Bone marrow invasion** |             |           |
| No                       | 1           |           |
| Yes                      | 0.48 (0.06, 9.92) | 0.532     |
| **Perineural invasion**  |             |           |
| No                       | 1           |           |
| Yes                      | 0.00 (0.00, Inf) | 0.994     |
| **Lymphovascular permeation** |         |           |
| No                       | 1           |           |
| Yes                      | 10.24 (1.59, 82.10) | 0.014     |
| **Depth of invasion**    | 0.84 (0.40, 1.18) | 0.523     |
| **Extra-nodal extension**|             |           |
| Yes                      | 1           |           |
| No                       | 2.89 (0.46, 56.03) | 0.339     |
| Ia                       |             |           |
| No                       | 1           |           |
| Yes                      | 7.07 (0.34, 54.12) | 0.095     |
| Ib                       |             |           |
| No                       | 1           |           |
| Yes                      | 0.90 (0.05, 5.48) | 0.921     |
| Ila                      |             |           |
| No                       | 1           |           |
| Yes                      | 9.80 (2.05, 52.10) | 0.004     |
| III                      |             |           |
| Continued                |             |           |
The prognostic importance of LVP in other solid tumors is well established and has been correlated with the development of distant metastases and survival31–33. LVP has been reported as a predictor for several well-known malignancies such as cervical, colorectal, and esophageal carcinomas34,35. It is also known to be associated with a high frequency of lymph node metastasis at the time of diagnosis and locoregional and distant metastatic recurrence in gastrointestinal and breast cancers36,37. Certain studies have emphasized preoperative assessment

| Variable          | Univariable |          |          |          |
|-------------------|-------------|----------|----------|----------|
|                   | OR (95% CI) | p value  |          |          |
| No                | 1           |          |          |          |
| Yes               | 11.77 (2.14, 59.11) | 0.003    |          |          |
| IV                |             |          |          |          |
| No                | 1           |          |          |          |
| Yes               | 17.92 (0.77, 214.95) | 0.026    |          |          |
| V                 |             |          |          |          |
| No                | 1           |          |          |          |
| Yes               | 17.92 (0.77, 214.95) | 0.026    |          |          |

**Table 3.** Logistic regression for IIb metastasis in the training group. OR, odds ratio; CI, confidence interval. pN pathologic N, cT clinical T, cN clinical N.

| Variable                  | Multivariable |          |          |          |
|---------------------------|---------------|----------|----------|----------|
| Lymphovascular permeation | OR (95% CI)   | p value  |          |          |
| No                        | 1             |          |          |          |
| Yes                       | 7.59 (1.01, 68.29) | 0.047    |          |          |
| IIa                       |               |          |          |          |
| No                        | 1             |          |          |          |
| Yes                       | 14.25 (1.91, 128.42) | 0.009    |          |          |

**Table 4.** Logistic regression for IIb metastasis in the training group. OR odds ratio, CI confidence interval.

**Figure 1.** Receiver operating characteristic curve based on the level IIb score to predict level IIb lymph node metastasis (n = 135, AUC: 0.697, P < 0.001).

The prognostic importance of LVP in other solid tumors is well established and has been correlated with the development of distant metastases and survival31–33. LVP has been reported as a predictor for several well-known malignancies such as cervical, colorectal, and esophageal carcinomas34,35. It is also known to be associated with a high frequency of lymph node metastasis at the time of diagnosis and locoregional and distant metastatic recurrence in gastrointestinal and breast cancers36,37. Certain studies have emphasized preoperative assessment
of LVP status in the therapeutic planning of breast cancers, noting that LVP status could help determine the need for sentinel lymph node biopsy and aggressive axillary lymph node dissections. With regard to oral carcinoma, however, LVP does not appear to have drawn much attention. Some studies have focused on LVP as an indicator of aggressive OSCC behavior along with perineural invasion (PNI); however, PNI was regarded as a more sensitive prognostic independent variable based on multivariate analysis. It was only recently that a large OSCC patient cohort retrospective study emphasized lymphatic invasion (LI) and vascular invasion (VI) as independent risk factors in survival and recurrence of OSCC. LVP is defined as groups of tumor cells attached to the lymphovascular vessel wall and projecting into the lumen of vessels in the capsule or outside the tumor. Although current guidelines do not incorporate LVP as an independent indication for adjuvant radiotherapy (RT) or chemotherapy (CRT), its consideration seems adequate for patients with biopsy-proven LVP. This is supported by a study of early OSCC wherein LVP was an independent risk factor for recurrence.

In order for the model to have predictive value and offer clinical criteria for surgical modality, however, it is important that risk factors be confirmed pre-operatively. Various methods of confirming one of our risk factors, level IIa metastasis, are well known, including preoperative assessment by clinical and radiological modalities and intraoperative diagnosis by use of frozen section. Moreover, sentinel node biopsy (SNB) is a well-established technique that allows the surgeon to identify and excise the upper echelon nodes that are subclinical. This technique, which has the potential to select patients for selective neck dissections, has an excellent safety profile and high sensitivity. Pre-operative confirmation of LVP, however, is rarely practiced, as main specimen analysis usually being done post-operatively. We would thus like to suggest possible methods of pre-operatively confirming LVP. The first and simplest choice is an incisional biopsy which includes sufficient peri-tumoral tissue for a pathologist to examine. Lympho-vascular permeation being a submucosal infiltration, it is vital to include the submucosal portion, with its lympho-vascular network; specimens must be obtained from several spots surrounding the tumor whenever possible to increase the probability of detecting LVP. Moreover, topological characteristic of the oral cavity must be taken into consideration because the thickness and width of submucosa varies along different sectors of the oral cavity. Algaba suggested that reliable vessel identification is possible using the hematoxylin and eosin (H&E) method provided that the observation is rigorous and all tested cases are subsequently confirmed by means of CD34. For difficult cases in which vessels are unidentifiable, an immunohistochemical procedure can be applied for ultimate confirmation. However, pre-operative incisional biopsy may not always provide enough information regarding peritumoral tissue and LVP status. Another method for pre-operative confirmation of LVP is MRI-based radiomics, whose medical images provide information about many quantitative features via high-throughput analysis, in which descriptive or predictive models of tumor characteristics are constructed based on selected features. A prediction model that incorporated both the radiomics signature and MRI axial lymph node status successfully predicted LVP status with an AUC of 0.763 in breast cancer. To the best of our knowledge, radiomics has not been actively applied in the field of OSCC. Further studies on radiomics and risk factors of OSCC are anticipated, not only with regard to predicting LVP status but also in predicting other pathologically ominous features that have been nearly undetectable pre-operatively.

There are myriads of reasons other researchers have been cautious about omitting level IIb dissection. First of all, Robbins proposed the classification of levels of neck to facilitate inter-institutional communication among surgeons, oncologists, and diagnostic radiologists abroad. The levels were defined according to anatomic landmarks instead of oncologic criteria or actual lymphatic flow. Lymph nodes of level Ia and IIb are part of the spinal accessory lymphatic and internal jugular lymphatic chains. The uppermost lymph nodes of the spinal accessory lymphatic chain overlap with the highest nodes of the internal jugular chain. Omitting parts of the nodes of the same lymphatic chain based on arbitrary anatomic landmarks does not seem reasonable from a therapeutic or oncologic standpoint. Secondly, Oikawa et al noted that all subsites of oral cancer may develop
retropharyngeal lymph node metastasis and that although rare, level IIb could constitute the first echelon node due to metastatic spread via the retropharyngeal lymphatic pathway\textsuperscript{52,53}. Thirdly, many studies emphasizing oncologic safety without dissecting level IIb seem to have overlooked the presence of micro-metastasis (MM) or isolated tumour cells (ITC) in the pN0 nodes\textsuperscript{54}. In a recent study, the rate of MM was as high as 9% in pN0 cases, the risk being highest in level IB and IIA\textsuperscript{55}. Moreover, current pre-operative diagnostics to detect nodal micro-metastasis are not definitive. To mention complications concerning the spinal accessory nerve, level IIb dissection cannot be solely blamed for shoulder syndrome. Cervical nerves distributed along cervical level II–IV may also contribute to innervation of the trapezius muscle in up to 39% of cases\textsuperscript{56}. Some authors have accordingly proposed that communications between cervical nerves and spinal accessory are responsible for
remaining trapezius muscle motor function even after radical neck dissection\textsuperscript{37}. Lastly, treatment modalities of OSCC, especially in managing the neck, are primarily based on TNM staging\textsuperscript{9}. Our common recognition on oral malignancy is that increasing T stage has a close to linear correlation with regional and distant metastasis. However, recent research on the mechanisms of metastasis reveal that early T stage cancers have high metastatic potential\textsuperscript{18,19}. There are certainly myriad of unveiled mechanism concerning cancer metastasis and proliferation and hasty generalizations regarding oncologic safety based on possibly loose statistics must be avoided.

Our study has several limitations. First, as a retrospective study, it may need further evaluation through a prospective study involving randomization in multiple centers. Second, a subgroup analysis including shoulder dysfunction would have increased the validity of our study. Thirdly, including clinically correlated numerical variables such as serum biomarkers would have maximized concreteness of predictive model and nomogram. Finally, although our predictive model was tested in a separate validation group and its fitness was confirmed, validation of our model with external data would have strengthened our findings. However, discovering LVP as prognostic factor of level IIb metastasis is fresh approach which can ignite further studies by supplementing aforementioned limitations.

Methods

Study participants. Our present study reviewed and collected medical records of patients who had undergone surgical treatment of OSCC at the Department of Oral and Maxillofacial Surgery, Yonsei University, from January 2000 to December 2020. Data of 541 biopsy-proven OSCC patients were obtained at this step. Patients with metastatic disease, secondary primary cancer, perioperative mortality, a history of previous radiotherapy or/and chemotherapy, or a history of previous head and neck cancer were excluded. The study group was further narrowed to OSCC patients who had undergone at least a unilateral selective lateral compartment dissection. The extent of neck dissection was determined according to the site, size and extent of the primary tumor and clinico-radiologic examination, including physical examination, as well as imaging techniques such as CT scanning, magnetic resonance (MRI) and PET-CT. The selective neck dissections (SNds) performed included level IIb in all patients. A unilateral neck dissection was performed unless there were metastases in both sides of the neck, the primary tumor crossed the midline, or when tumors arose from the base of the tongue or floor of mouth. All surgical specimens were post-operatively sub-dissected according to sublevels and sent to the Department of Oral Pathology for evaluation. Every neck dissection was performed according to the anatomical and surgical boundaries suggested by Robbins et al.\textsuperscript{15}. Patients with following adverse post-operative risk features were considered for adjuvant chemo-radiotherapy: pN positive, positive margin, perineural infiltration, vascular embolization, perineural infiltration, lymphovascular permeation and huge pathologic T3 or T4 lesions. Post-operative patient surveillance policy of our institute includes follow-up visits every 3 months for the first year, 2–6 months for the second year and every 4–8 months for the third to fifth year and finally annual visits after the fifth year. After excluding 182 for insufficient data (44) or meeting the exclusion criteria (138; patients treated without neck dissection), a total of 359 patients’ data were suitable for analysis. The study was approved by the Ethics Review Board of Yonsei University Dental Hospital Institutional Review Board (IRB No. 2-2020-0036). All research was performed in accordance with guidelines proposed in Declaration of Helsinki. However, Written or verbal informed consent was not obtained from any participants because Ethics Review Board of Yonsei University Dental Hospital Institutional Review Board waived the need for individual informed consent, as this study had a non-interventional retrospective design and all data were analyzed anonymously.

Statistical analysis. The statistical analysis was performed using SAS V9.4 (SAS Institute, Cary NC, USA) and R package, version 4.0.4 (R Project for Statistical Computing, Vienna, Austria). Baseline differences between the training set and validation set were assessed using the Independent two sample t-test or Mann–Whitney U test for continuous variables and Chi-square test and Fisher’s exact test for categorical variables. Potential clinico-pathologic risk factors associated with level IIb lymph node metastasis in the 359-patient neck dissection group were assessed by logistic regression test.

Survival curves were plotted to estimate the prognostic effect of LVP and level IIa metastasis on overall survival and recurrence using Cox proportional hazard regression.

Modelling process. Prior to building a prediction model, we split the data into two mutually exclusive sets. Approximately 65% of the overall dataset was designated the training set and was utilized to generate the prediction model. The remaining 35% of the data constituted the validation set, for use in estimating the model’s accuracy. Harrell’s c-index was used to elucidate the performance of the proposed method. Model fitness was verified via Chi-square test.

Received: 11 June 2021; Accepted: 12 August 2021
Published online: 02 September 2021

References

1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68, 394–424 (2018).
2. Califano, J. et al. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res. 56, 2488–2492 (1996).
3. Ferlito, A., Silver, C. E. & Rinaldo, A. Neck dissection in the new era. J. Am. Coll. Surg. 204, 466–468 (2007).
4. Brentani, R. R. et al. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. Am. J. Surg. 176, 422–427 (1998).
5. Spiro, J. D., Spiro, R. H., Shad, J. P., Sessions, R. B. & Strong, E. W. Critical assessment of supraglottic larynx neck dissection. Am. J. Surg. 156, 286–289 (1988).
6. Foul, B. J. et al. Neck dissection in the nineteenth century. Eur. Arch. Oto-Rhino-Laryngol. 264, 455–460 (2007).
7. Robbins, K. T. et al. The evolving role of selective neck dissection for head and neck squamous cell carcinoma. Eur. Arch. Otorhinolaryngol. 270, 1195–1202 (2013).
8. Penarrocha, M., Garcia, B., Marti, E. & Balague, J. Pain and inflammation after periperal surgery in 60 patients. J. Oral Maxillofac. Surg. 64, 429–433 (2006).
9. Pantvaidya, G., Rao, K. & D’Cruz, A. Management of the neck in oral cancers. Oral Oncol. 100, 104746 (2020).
10. Førliö, A. et al. Proposal for a rational classification of neck dissections. Head Neck 33, 445–450 (2011).
11. Førliö, A. & Rinaldo, A. Osvaldo Suarez: often forgotten father of functional neck dissection (in the non-spanish-speaking literature). Laryngoscope 114, 1177–1178 (2004).
12. Brentani, R. R. et al. End results of a prospective trial on elective lateral neck dissection vs type III modified radical neck dissection in the management of supraglottic and transglottic carcinomas. Head Neck 21, 694–702 (1999).
13. Lim, Y. C., Song, M. H., Kim, S. C., Kim, K. M. & Choi, E. C. Preserving level IIb lymph nodes in elective supraglottic laryngeal neck dissection for oral cavity squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 130, 1088–1091 (2004).
14. Elsheikh, M. N. et al. Elective supraglottic neck dissection for oral cavity squamous cell carcinoma: Is dissection of sublevel IIb necessary? Oral Oncol. 44, 216–219 (2008).
15. Thomas Robbins, K. et al. Neck dissection classification update: Revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology–Head and Neck Surgery. Arch. Otolaryngol. Head Neck Surg. 128, 751–758 (2002).
16. Byers, R. M., Wolf, P. F. & Ballantyne, A. J. Rationale for elective modified neck dissection. Head Neck Surg. 10, 160–167 (1988).
17. Shah, J. P., Candela, F. C. & Podlar, A. K. The Patterns. 109–113 (1986).
18. Nikolakos, D. & Bell, R. B. Management of the node-positive neck in oral cancer. Oral Maxillofac. Surg. Clin. N. Am. 20, 499–511 (2008).
19. López, F. et al. Selective neck dissection in the treatment of head and neck squamous cell carcinoma patients with a clinically positive neck. Oral Oncol. 102, 104565 (2020).
20. Shah, J. P. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am. J. Surg. 160, 405–409 (1990).
21. Lloyd, S. Accessory nerve: Anatomy and surgical identification. J. Laryngol. Otol. 121, 1118–1125 (2007).
22. Cheng, P. T., Lin, Y. H., Hao, S. P. & Yeh, A. R. M. Objective comparison of shoulder dysfunction after three neck dissection techniques. Ann. Otol. Rhinol. Laryngol. 109, 761–766 (2000).
23. Lea, J. et al. Metastases to level IIb in squamous cell carcinoma of the oral cavity: a systematic review and meta-analysis. Head Neck 32, 184–190 (2010).
24. Paleri, V., Kumar Subramaniam, S., Oozer, N., Rees, G. & Krishnan, S. Dissection of the submental recess (sublevel IIb) in squamous cell cancer of the upper aerodigestive tract: Prospective study and systematic review of the literature. Head Neck 30, 194–200 (2008).
25. Dźięgielewski, P. T. et al. 2b or not 2b? Shoulder function after level 2b neck dissection: A double-blind randomized controlled trial. Cancer 126, 1492–1501 (2020).
26. Pandey, M., Karhikeyan, S., Joshi, D., Kumar, M. & Shukla, M. Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World J. Surg. Oncol. 16, 1–9 (2018).
27. Giordano, L., Sarandria, D., Fabiano, B., Del Carro, U. & Bussi, M. Shoulder function after selective and supralselective neck dissections: Clinical and functional outcomes. Acta Otorhinolaryngol. Ital. 32, 376–379 (2012).
28. Koerdl, S. et al. Lymph node management in the treatment of oral cancer: Analysis of a standardized approach. J. Cranio-Maxillofac. Surg. 44, 1737–1742 (2016).
29. Manola, M. et al. Status of level IIb lymph nodes of the neck in squamous cell carcinoma of the oral tongue in patients who underwent modified radical neck dissection and lymph node sentinel biopsy. Acta Otorhinolaryngol. Ital. 31, 130–134 (2011).
30. Pantvaidya, G. H., Pal, P., Vaidya, A. D., Pai, P. S. & D’Cruz, A. K. Prospective study of 585 neck dissections in oral cancers: Implications for clinical practice. Head Neck 36, 1503–1507 (2014).
31. Algaba, F. Lymphovascular invasion as a prognostic tool for advanced bladder cancer. Curr. Opin. Urol. 16, 367–371 (2006).
32. Kim, J. M. et al. Lymphovascular invasion is associated with lateral cervical lymph node metastasis in papillary thyroid carcinoma. Laryngoscope 116, 2081–2085 (2006).
33. Woo, C. S. et al. Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer. Am. J. Surg. 184, 337–340 (2002).
34. Sakuragi, N. et al. A multivariate analysis of blood vessel and lymph vessel invasion as predictors of ovarian and lymph node metastases in patients with cervical carcinoma. Cancer 88, 2578–2583 (2000).
35. Natsugoe, S. et al. Prognostic factors in patients with submucosal esophageal cancer. J. Gastrointest. Surg. 8, 631–635 (2004).
36. Okuyama, T., Moriguchi, S., Tsutisani, S. & Korenaga, D. Predictors of lymph node metastasis in early gastric cancer. J. Br. Surg. 79, 245–247 (1992).
37. Lee, A. K. C., DeLellis, R. A., Silverman, M. L., Heatley, G. J. & Wolfe, H. J. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J. Clin. Oncol. 8, 1457–1465 (1990).
38. Weiser, M. R. et al. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann. Surg. Oncol. 8, 14–19 (2001).
39. Ryu, J. M. et al. Predictive factors for nonsentinel lymph node metastasis in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy: Nomogram for predicting nonsentinel lymph node metastasis. Clin. Breast Cancer 17, 550–558 (2017).
40. Jones, H. B. et al. The impact of lymphovascular invasion on survival in oral carcinoma. Oral Oncol. 45, 10–15 (2009).
41. Woolgar, J. A. Histopathological prognosticators in oral and oropharyngeal squamous cell carcinoma. Oral Oncol. 42, 229–239 (2006).
42. Binnadi, N. O. & Basile, J. R. Perineural invasion in oral squamous cell carcinoma: A discussion of significance and review of the literature. Oral Oncol. 47, 1005–1010 (2011).
43. Massano, J., Regateiro, F. S., Januário, G. & Ferreira, A. Oral squamous cell carcinoma: Review of prognostic and predictive factors. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol. 102, 67–76 (2006).
44. Spoerl, S. et al. Lymphatic and vascular invasion in oral squamous cell carcinoma: Implications for recurrence and survival in a population-based cohort study. Oral Oncol. 111, 105069 (2020).
45. Kerawala, C., Roques, T., Jeannon, J. P. & Bisaccia, B. Oral cavity and lip cancer: United Kingdom national multidisciplinary guidelines. J. Laryngol. Otol. 130, 583–589 (2016).
46. Huang, T. Y. et al. Predictors of locoregional recurrence in early stage oral cavity cancer with free surgical margins. Oral Oncol. 46, 49–55 (2010).
47. Roma, A. A. et al. Peritumoral lymphatic invasion is associated with regional lymph node metastases in prostate adenocarcinoma. Mod. Pathol. 19, 392–398 (2006).
48. Gillies, R. J., Kinahan, P. E. & Hricak, H. Radiomics: Images are more than pictures, they are data. Radiology 278, 563–577 (2016).
49. Huang, Y. Q. et al. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J. Clin. Oncol. 34, 2157–2164 (2016).
50. Liu, Z. et al. Preoperative prediction of lymphovascular invasion in invasive breast cancer with dynamic contrast-enhanced-MRI-based radiomics. J. Magn. Reson. Imaging 50, 847–857 (2019).

51. Skolnik, E. M., Yee, K. F., Friedman, M. & Golden, T. A. The posterior triangle in radical neck surgery. Arch. Otolaryngol. 102, 1–4 (1976).

52. Oikawa, Y. et al. Management of retropharyngeal lymph node metastasis in oral cancer. Oral Oncol. 99, 104471 (2019).

53. Umeda, M. et al. Metastasis to the lingual lymph node in patients with squamous cell carcinoma of the floor of the mouth: A report of two cases. Köbe J. Med. Sci. 55, 67–72 (2009).

54. Subash, A., Singh, A. & Sinha, P. The omission of level IIB in early oral cancers: A word of caution. J. Stomatol. Oral Maxillofac. Surg. https://doi.org/10.1016/j.joms.2020.05.023 (2020).

55. Majumdar, K. S. et al. Incidence of micrometastasis and isolated tumour cells in clinicopathologically node-negative head and neck squamous cell carcinoma. J. Maxillofac. Oral Surg. 19, 131–135 (2020).

56. Lanišnik, B. Different branching patterns of the spinal accessory nerve: Impact on neck dissection technique and postoperative shoulder function. Curr. Opin. Otolaryngol. Head Neck Surg. 25, 113–118 (2017).

57. Pu, Y. M., Tang, E. Y. & Yang, X. D. Trapezius muscle innervation from the spinal accessory nerve and branches of the cervical plexus. Int. J. Oral Maxillofac. Surg. 37, 567–572 (2008).

58. Lee, Y. et al. Dishevelled has a YAP nuclear export function in a tumor suppressor context-dependent manner. Nat. Commun. 9, 1–16 (2018).

**Author contributions**

W.N. and S.H.L. conceived idea. H.J.K., I.C., D.K., S.H.L. and W.N. contributed in data acquisition and interpretation. H.Y. and N.–H.S. contributed in statistical analysis and preparation of figures. H.Y. analyzed the data, built prediction models, wrote the main manuscript text. W.N. provided expert guidance for all aspects of the study and critical revision of the article. All authors reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to W.N.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021